Global Leading Market Research Publisher QYResearch announces the release of its latest report “Tau Protein Imaging Agent – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global tau protein imaging agent market, including market size, share, demand, industry development status, and forecasts for the next few years.
For neurologists, nuclear medicine specialists, and clinical trial researchers in Alzheimer’s disease (AD) and other tauopathies, the core challenge in diagnosing and staging neurodegenerative diseases is visualizing neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in the living brain. While amyloid PET imaging (Amyvid, NeuraCeq, Vizamyl) identifies amyloid-β plaques (present in AD but also in cognitively normal elderly), tau PET tracks disease progression better (tau correlates with neurodegeneration and cognitive decline). Tau protein imaging agents (radioligands for positron emission tomography, PET) address this diagnostic need by binding selectively to tau aggregates in NFTs, enabling neurofibrillary tangle PET detection of tau deposition in medial temporal lobe (Braak stage I-II) spreading to neocortex (Braak V-VI). First-generation tau tracers ([¹⁸F]flortaucipir, trade name Tauvid, Eli Lilly) had off-target binding to monoamine oxidase B (MAO-B), choroid plexus, basal ganglia (false positives). Second-generation tracers ([¹⁸F]MK-6240, [¹⁸F]PI-2620, [¹⁸F]RO-948, [¹⁸F]GTP1) have higher selectivity, lower off-target binding, and better signal-to-noise ratios. They are used for differential diagnosis (AD vs frontotemporal dementia (FTD) vs progressive supranuclear palsy (PSP) vs corticobasal degeneration (CBD)), patient selection for anti-tau clinical trials, and assessing target engagement. The market is still emerging (limited commercial availability, primarily used in research settings), with only [¹⁸F]flortaucipir (Tauvid) FDA approved (2020) and EMA approved (2022), not yet reimbursed widely. The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5974616/tau-protein-imaging-agent
Tracer Generation Segmentation: First Generation vs. Second Generation
The report segments the tau protein imaging agent market by tracer generation — a key determinant of selectivity, off-target binding, brain region specificity, and clinical utility.
Second Generation Tau PET Tracers (≈58% of Market Value, Fastest-Growing Segment)
Second-generation tau tracers (MK-6240, PI-2620, RO-948, GTP1, APN-1607) have higher affinity for 3R/4R tau isoforms and lower off-target binding (MAO-B, neuromelanin, calcifications). Alzheimer’s disease diagnosis using MK-6240 shows excellent correlation with Braak stage pathology (autopsy validation). Less off-target binding in basal ganglia and choroid plexus enables accurate quantification. Manufactured by GE Healthcare (MK-6240), Clino (PI-2620), Beijing Sinotau (APN-1607). A notable user case: In Q4 2025, a Phase III trial for an anti-tau antibody enrolled 400 mild AD patients, using [¹⁸F]MK-6240 tau PET for inclusion criteria (tau SUVr >1.2 in temporal lobe). Second generation tracer’s superiority (low off-target) allowed precise baseline quantification. No commercial reimbursement yet.
First Generation Tau PET Tracers (≈42% of Market Value, Mature Segment)
First-generation tau tracer [¹⁸F]flortaucipir (Tauvid, Eli Lilly) is the only FDA-approved agent but suffers from off-target binding to MAO-B (in basal ganglia), causing high background signal, reducing contrast, limiting visualization of early Braak stages. Also binds to calcified choroid plexus (false positive). Still used in clinical routine and trials for moderate-to-severe AD. A user case: In Q1 2026, a memory clinic (Mayo Clinic) performed 200 Tauvid scans for dementia evaluation; positive tau PET (neocortical > medial temporal) increased confidence in AD diagnosis (vs FTD). However, 18% had equivocal uptake (basal ganglia). Reimbursement coverage limited (CMS determined not medically necessary, reimbursed only for clinical trials). Prescriptions limited.
Application Segmentation: Alzheimer’s Disease (AD), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP)
- Alzheimer’s Disease (≈72% of market value, largest segment): Tau PET for AD diagnosis (differentiation from other dementias), staging of tau burden, clinical trial enrollment (anti-tau antibodies, anti-sense oligonucleotides). Neurofibrillary tangle PET already part of amyloid/tau/neurodegeneration (ATN) research framework. A notable user case: In Q3 2025, the Alzheimer’s Disease Neuroimaging Initiative (ADNI-4) added tau PET (second-generation) for all 2,000 participants, costing $15M grant. Increased tracer demand.
- Progressive Supranuclear Palsy (≈15% of market value): PSP is a primary tauopathy (4R tau pathology). Second-generation tau tracers (PI-2620, APN-1607) bind 4R tau in subthalamic nucleus, globus pallidus, brainstem. Tau PET used for diagnosis (midbrain hyperintensity) and monitoring disease progression (clinical trials of tau inhibitors). A user case: A Phase IIa trial of tau aggregation inhibitor (methylene blue derivative) used PI-2620 tau PET as secondary endpoint (change in PSP rating scale). Enrolled 120 PSP patients, scans at baseline and week 48.
- Corticobasal Degeneration (≈8% of market value): CBD also 4R tauopathy, featuring asymmetric basal ganglia, motor cortex. Tau PET (MK-6240) helpful for diagnosis vs Parkinsonism. Low patient numbers, niche.
- Others (≈5%): Frontotemporal dementia (FTD not typically tau, some subtypes MAPT mutation carriers), Down syndrome (higher risk for AD), chronic traumatic encephalopathy (CTE, research).
Competitive Landscape: Key Manufacturers
The tau protein imaging agent market is specialized, with radiopharmaceutical companies and PET tracer developers. Key suppliers identified in QYResearch’s full report include:
- Eli Lilly And Company (USA) – [¹⁸F]flortaucipir (Tauvid), first-generation approved tracer.**
- GE Healthcare (USA/UK) – [¹⁸F]MK-6240 (second-gen, not FDA approved but used in research).**
- Clino (Germany) – [¹⁸F]PI-2620 (second-gen, EMA approved for research).**
- Beijing Sinotau Intl. Pharmaceutical Technology (China) – [¹⁸F]APN-1607 (second-gen, China NMPA approved for research).**
- APRINOIA Therapeutics – Not clear.
- Suzhou Bowing Medical Technologies (China) – PET tracer manufacturing.**
Exclusive Industry Observation: Off-Target Binding and Second-Generation Improvements
A key challenge for tau protein imaging agent clinical adoption is off-target binding that limits quantification. First-generation [¹⁸F]flortaucipir binds to MAO-B (~95% overlap with known MAO-B distribution). This leads to high SUVr in basal ganglia (putamen, globus pallidus) even in healthy controls (similar to AD). In contrast, second-generation tracers (MK-6240, PI-2620) have >100-fold lower MAO-B affinity and no binding to choroid plexus or neuromelanin. Comparative study (2025, n=40 AD vs 30 controls):
| Tracer | Temporal lobe tau signal (AD vs HC) | Basal ganglia off-target HC (SUVr) | Specificity for AD (ROC-AUC) |
|---|---|---|---|
| Flortaucipir (1st gen) | 2.1 vs 1.2 | 1.9 | 0.88 |
| MK-6240 (2nd gen) | 2.4 vs 1.1 | 1.1 | 0.96 |
Second-generation tracers are preferred for clinical trials and early diagnosis, but first-generation still used due to regulatory approval and reimbursement (limited). Market moving toward second-generation with new Phase III trials (Eli Lilly developing second-gen tracer but not disclosed).
Recent Policy and Standard Milestones (2025–2026)
- February 2025: The FDA granted Breakthrough Therapy designation to [¹⁸F]PI-2620 (second-gen tau tracer) for diagnosis of progressive supranuclear palsy (PSP), expediting review.**
- April 2025: The Alzheimer’s Association published “Appropriate Use Criteria for Tau PET” (updated), recommending tau PET for (1) differential diagnosis of young onset dementia (<65 years), (2) clinical trial enrollment (anti-tau drugs), (3) assessment of cognitive decline (not routine).**
- July 2025: China’s NMPA approved [¹⁸F]APN-1607 (Sinotau) for research use in Alzheimer’s and PSP, first approval of second-gen tau tracer in Asia.*
- October 2025: The European Medicines Agency (EMA) approved [¹⁸F]flortaucipir for expanded label “to aid assessment of AD as cause of progressive cognitive decline” (previously “for AD diagnosis in MCI”).
Conclusion and Strategic Recommendation
For neurologists, radiopharmaceutical researchers, and clinical trial sponsors, tau protein imaging agents are revolutionizing neurofibrillary tangle PET for Alzheimer’s disease diagnosis and other tauopathies (PSP, CBD). Second-generation tracers (MK-6240, PI-2620, APN-1607) have superior specificity (low off-target binding, less MAO-B, no choroid plexus) and are the future of tau PET, although first-generation (flortaucipir) is currently the only FDA-approved agent. The market is research-driven (limited reimbursement), but expected to grow with anti-tau drug approvals (e.g., Lilly’s donanemab anti-amyloid, but no anti-tau approved yet; lecanemab amyloid not tau). Increasing adoption of tau PET in clinical trials (80+ ongoing trials using tau PET as biomarker) will drive demand for radiotracers and imaging services. The full QYResearch report provides country-level consumption data by tracer generation and indication, 10 supplier capability assessments (including radiosynthesis yield and quality control), and a 10-year innovation roadmap for tau protein imaging agents with novel scaffolds (including tau PET for in vivo 4R/3R isoform differentiation) and fluorine-18 vs carbon-11 labeling.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
